Compare Dollar Tree, Inc. (DLTR) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar Tree, Inc. vs Revvity Inc — how do they compare? Dollar Tree, Inc. trades at $118.64 (market cap $22.26B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Dollar Tree, Inc. is the larger of the two by market cap, and Revvity Inc pays a 0.18% dividend while Dollar Tree, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dollar Tree, Inc. for 58 Days and Revvity Inc for 12 Days on average.
| DLTR | RVTY | |
|---|---|---|
Market Cap | $22.26B | $16.98B |
Volume | 2,317,428 | 1,456,900 |
Sector | Consumer Staples | Health |
52-Week High | $141.21 | $157.36 |
52-Week Low | $86.80 | $82.26 |
Typical Hold Time | 58 Days | 12 Days |
Enterprise Value | $28.87B | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar Tree (DLTR) trades at $118.62, up 1.99% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust profitability with a 45.87% ROE and trades at a reasonable P/E of 14.54. Recent news highlights strategic initiatives and store expansions driving growth, while net cash flow improved to $754 million in 2025. Analysts maintain a buy consensus with a $139.33 price target, indicating potential upside from current levels.
Outlook is positive due to earnings momentum and value-focused strategy, but risks include margin pressure from tariffs and rising costs. The stock offers growth potential if execution continues, though investors should monitor competitive pressures and economic sensitivity. Institutional buying supports confidence, but volatility near resistance at $120 requires caution.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
